Client update: Hibergene

Ruffena client Hibergene Diagnostics (HG) has achieved subscription for target capital sought and is offering an oversubscription of £500k EIS qualifying shares.

At the same time HG is launching its third diagnostic product, a test for Group B Streptococcus (GBS). A GBS test can be crucial for women approaching labour because it guides treatment that can avert baby deaths and disabilities. The HG test is significantly more accurate, less expensive, quicker and more convenient than the nearest competing product.

Click here or contact Simon Heywood for HG investment documentation.